Stockscreener 앱 받기
147.90
6.04%
8.42
시간 외 거래:
148.54
0.64
+0.43%
전일 마감가:
$139.48
열려 있는:
$141.15
하루 거래량:
2.42M
Relative Volume:
0.86
시가총액:
$31.44B
수익:
$742.00K
순이익/손실:
$-1.13B
주가수익비율:
-25.00
EPS:
-5.9165
순현금흐름:
$-913.73M
1주 성능:
+12.33%
1개월 성능:
+49.21%
6개월 성능:
+152.52%
1년 성능:
+263.21%
1일 변동 폭
$140.95
$148.25
1주일 범위
$138.75
$150.00
52주 변동 폭
$34.00
$155.70
Revolution Medicines Inc Stock (RVMD) Company Profile
명칭
Revolution Medicines Inc
전화
650-481-6801
주소
700 SAGINAW DR, REDWOOD CITY, CA
Compare RVMD vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
147.90 | 29.65B | 742.00K | -1.13B | -913.73M | -5.9165 |
VRTX
Vertex Pharmaceuticals Inc
|
429.85 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
709.21 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
811.09 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.93 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.14 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-16 | 재개 | Jefferies | Buy |
| 2026-02-27 | 재개 | UBS | Buy |
| 2025-11-18 | 개시 | Wolfe Research | Outperform |
| 2025-11-03 | 개시 | RBC Capital Mkts | Outperform |
| 2025-10-21 | 개시 | Mizuho | Outperform |
| 2025-10-16 | 재개 | Stifel | Buy |
| 2025-09-12 | 재개 | Raymond James | Strong Buy |
| 2025-09-05 | 개시 | Truist | Buy |
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2025-08-15 | 개시 | Wells Fargo | Overweight |
| 2025-07-15 | 개시 | Goldman | Buy |
| 2024-07-16 | 재확인 | Needham | Buy |
| 2024-07-12 | 개시 | Barclays | Overweight |
| 2024-07-08 | 개시 | Jefferies | Buy |
| 2024-04-12 | 재확인 | Needham | Buy |
| 2024-04-10 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-03-11 | 개시 | Piper Sandler | Overweight |
| 2024-01-05 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-01-04 | 개시 | Wedbush | Outperform |
| 2023-11-16 | 개시 | Raymond James | Outperform |
| 2023-02-28 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-12-14 | 개시 | Needham | Buy |
| 2022-10-21 | 개시 | Oppenheimer | Outperform |
| 2022-05-20 | 개시 | BofA Securities | Neutral |
| 2022-03-01 | 업그레이드 | Stifel | Hold → Buy |
| 2021-09-23 | 개시 | Stifel | Hold |
| 2021-08-12 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-05-18 | 개시 | Goldman | Buy |
| 2020-05-21 | 개시 | H.C. Wainwright | Buy |
| 2020-03-09 | 개시 | Cowen | Outperform |
| 2020-03-09 | 개시 | Guggenheim | Buy |
| 2020-03-09 | 개시 | JP Morgan | Neutral |
모두보기
Revolution Medicines Inc 주식(RVMD)의 최신 뉴스
Are These 5 Biotech Stocks Set to Beat Q1 Earnings Estimates? - TradingView
Revolution Medicines Files Patent Infringement Lawsuit Against Erasca - HarianBasis.co
Revolution Medicines, Inc. (RVMD) One of the Best Stocks to Buy in a Rising Market amid $14B Opportunity - Insider Monkey
Revolution Medicines Inc. (RVMD): Billionaire Tom Steyer Remains Bullish on This Stock - Yahoo Finance
Jennison Associates LLC Takes $24.31 Million Position in Revolution Medicines, Inc. $RVMD - MarketBeat
Revolution Medicines' Pancreatic-Cancer Drug Cleared for Expanded Access - Moomoo
US FDA authorizes early access to Revolution's pancreatic cancer pill - Reuters
Revolution Medicines Advances Pancreatic Cancer Treatment with Daraxonrasib - GuruFocus
Revolution Medicines (RVMD) Gains FDA Approval for Daraxonrasib in Pancreatic Cancer - GuruFocus
Revolution Medicines receives FDA early access authorization for pancreatic cancer pill - Investing.com Canada
Revolution Medicines (RVMD) Advances with FDA Approval for Expan - GuruFocus
Stifel Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $215 - Moomoo
The U.S. Food and Drug Administration (FDA) has issued a "safe to proceed" letter to Revolution Medicines, Inc., approving the initiation of an expanded access program for its investigational drug Daraxonrasib for the treatment of pancreatic cancer patients. - Bitget
Revolution Medicines' cancer drug made available in U.S. - Seeking Alpha
F.D.A. grants early access to Revolution Medicines promising drug Daraxonrasib for pancreatic cancerNYT - marketscreener.com
Revolution Medicines, Inc. $RVMD Shares Bought by Vanguard Group Inc. - MarketBeat
First RAS Inhibitor Extends Survival in Previously Treated Metastatic Pancreatic Adenocarcinoma: What You Need to Know - Pancreatic Cancer Action Network
Revolution Medicines Data Updates Refocus Investor Attention On RAS Pipeline Potential - simplywall.st
Revolution Medicines (RVMD) price target increased by 10.02% to 136.84 - MSN
Revolution Medicines rival Erasca falls after early-stage trial data for cancer therapy - MSN
Revolution Medicines’ Anthony Mancini sells $413k in shares By Investing.com - Investing.com India
Revolution Medicines’ Anthony Mancini sells $413k in shares - Investing.com
Revolution Medicines (RVMD) insider sells 3,120 shares after exercising options - Stock Titan
Revolution Medicines sets May 6 webcast for Q1 results, corporate update - Stock Titan
ERAS Stock Slumps Nearly 40% After-Hours: Fine Print In 'Positive' Cancer Trial Reveals Treatment-Related Death - Stocktwits
Universal Beteiligungs und Servicegesellschaft mbH Has $5.23 Million Stake in Revolution Medicines, Inc. $RVMD - MarketBeat
Revolution Medicines has a market cap of $29 billion and generates no revenue. Here's why its valuation may not be as ridiculous as it seems - MSN
Pictet Asset Management Holding SA Reduces Stake in Revolution Medicines, Inc. $RVMD - MarketBeat
Revolution Medicines, Inc. $RVMD Shares Bought by UBS Group AG - MarketBeat
Revolution Medicines (RVMD) Expected to Announce Earnings on Wednesday - MarketBeat
RVMD Technical Analysis | Trend, Signals & Chart Patterns | REVOLUTION MEDICINES INC (NASDAQ:RVMD) - ChartMill
Revolution Medicines (RVMD) price target increased by 29.89% to 177.75 - MSN
Revolution Medicines plans $1B combined equity and convertible note offerings - MSN
Erasca Stock Sinks 48% in Race for Pancreatic Cancer Miracle Drug. What’s Behind the Sell-Off. - Barron's
RVMD Stock Rallies As Daraxonrasib Data Ignite Wall Street - StocksToTrade
RVMD Stock Rallies As Daraxonrasib Data Fuels Bullish Re‑Rating - timothysykes.com
Biotech Momentum Sparks Attention Beyond Nasdaq Composite - Kalkine Media
Assessing Revolution Medicines (RVMD) Valuation After Positive RASolute 302 And Zoldonrasib Clinical Updates - Yahoo Finance
There’s a Revolution in Cancer. But Can Big Pharma Afford It? - WSJ
Revolution Medicines (NASDAQ:RVMD) Shares Gap Up After Analyst Upgrade - MarketBeat
RVMD Stock Climbs As Daraxonrasib Data Ignite Street Targets - StocksToTrade
Why Is Cancer Drug Developer Erasca Stock Plunging On Tuesday? - Benzinga
High-flying Revolution Medicines threatens to sue a cancer drug competitor with licensed Chinese drug - The Business Journals
[ARS] Revolution Medicines, Inc. SEC Filing - Stock Titan
Revolution Medicines (NASDAQ:RVMD) Raised to Strong-Buy at Truist Financial - MarketBeat
Calamos Advisors LLC Takes $992,000 Position in Revolution Medicines, Inc. $RVMD - MarketBeat
RVMD Stock Price, Quote & Chart | REVOLUTION MEDICINES INC (NASDAQ:RVMD) - ChartMill
Revolution Medicines Trial Updates Spark Fresh Interest In RAS Focused Pipeline - Yahoo Finance
AbbVie says not in talks to buy Revolution Medicinesreport - MSN
RVMDW Price History for Revolution Medicines WT Stock - Barchart
Merck ends talks to buy Revolution Medicines, WSJ reports - MSN
Revolution Medicines Inc (RVMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
5.07%
자본화:
|
볼륨(24시간):